IGFBP2 and ovarian carcinoma: Currently, a NCI-sponsored Phase I clinical trial is in progress to test the safety and immunogenicity of an IGFBP2-encoding DNA plasmid-based vaccine in patients with advanced stage or recurrent ovarian cancer, with the hopes of generating an IGFBP2-specific Th1 immune response (NCT01322802).